Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ines Kaupe

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
Nature Chemical Biology|January 31, 2012
BCR-ABL uncouples canonical JAK2-STAT5 signaling in chronic myeloid leukemiaOliver Hantschel, Wolfgang Warsch, Eva Eckelhart, et al.
Molecular Oncology|April 23, 2009
The chemokine interleukin-8 and the surface activation protein CD69 are markers for Bcr-Abl activity in chronic myeloid leukemiaOliver Hantschel, Agnes Gstoettenbauer, Jacques Colinge, et al.
Proceedings of the National Academy of Sciences of the United States of America|April 22, 2009
Charting the molecular network of the drug target Bcr-AblMarc Brehme, Oliver Hantschel, Jacques Colinge, et al.
BMC Systems Biology|January 29, 2011
Initial characterization of the human central proteomeThomas R Burkard, Melanie Planyavsky, Ines Kaupe, et al.
Nature Structural & Molecular Biology|April 2, 2010
A potent and highly specific FN3 monobody inhibitor of the Abl SH2 domainJohn Wojcik, Oliver Hantschel, Florian Grebien, et al.
Blood|August 28, 2007
Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targetsUwe Rix, Oliver Hantschel, Gerhard Dürnberger, et al.
Blood|June 4, 2010
BCR-ABL SH3-SH2 domain mutations in chronic myeloid leukemia patients on imatinibDaniel W Sherbenou, Oliver Hantschel, Ines Kaupe, et al.
Cell|October 18, 2011
Targeting the SH2-kinase interface in Bcr-Abl inhibits leukemogenesisFlorian Grebien, Oliver Hantschel, John Wojcik, et al.
Genome Biology|August 2, 2013
Experimental characterization of the human non-sequence-specific nucleic acid interactomeGerhard Dürnberger, Tilmann Bürckstümmer, Kilian Huber, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Nature Chemical Biology|January 31, 2012
BCR-ABL uncouples canonical JAK2-STAT5 signaling in chronic myeloid leukemiaOliver Hantschel, Wolfgang Warsch, Eva Eckelhart, et al.
Molecular Oncology|April 23, 2009
The chemokine interleukin-8 and the surface activation protein CD69 are markers for Bcr-Abl activity in chronic myeloid leukemiaOliver Hantschel, Agnes Gstoettenbauer, Jacques Colinge, et al.
Proceedings of the National Academy of Sciences of the United States of America|April 22, 2009
Charting the molecular network of the drug target Bcr-AblMarc Brehme, Oliver Hantschel, Jacques Colinge, et al.
BMC Systems Biology|January 29, 2011
Initial characterization of the human central proteomeThomas R Burkard, Melanie Planyavsky, Ines Kaupe, et al.
Nature Structural & Molecular Biology|April 2, 2010
A potent and highly specific FN3 monobody inhibitor of the Abl SH2 domainJohn Wojcik, Oliver Hantschel, Florian Grebien, et al.
Blood|August 28, 2007
Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targetsUwe Rix, Oliver Hantschel, Gerhard Dürnberger, et al.
Blood|June 4, 2010
BCR-ABL SH3-SH2 domain mutations in chronic myeloid leukemia patients on imatinibDaniel W Sherbenou, Oliver Hantschel, Ines Kaupe, et al.
Cell|October 18, 2011
Targeting the SH2-kinase interface in Bcr-Abl inhibits leukemogenesisFlorian Grebien, Oliver Hantschel, John Wojcik, et al.
Genome Biology|August 2, 2013
Experimental characterization of the human non-sequence-specific nucleic acid interactomeGerhard Dürnberger, Tilmann Bürckstümmer, Kilian Huber, et al.
Pageof 1